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Abstract
Background: In North America, the harms of illicit drug use have been responded to primarily
through law enforcement interventions. This strategy has resulted in record populations of
addicted individuals being incarcerated in both Canada and the United States. The incarceration of
non-violent drug offenders has become increasingly controversial as studies demonstrate the
harms, including elevated HIV risk behavior, of incarcerating injection drug users. Other harms,
such as the initiation of illicit drug use by prison inmates who previously did not use drugs, have
been less commonly described.
Case Presentation: We report on the case of an individual who initiated non-injection opiate
use in a Canadian prison and developed an addiction to the drug. Upon release into the community,
the individual continued using opiates and sought treatment at a clinic. The patient feared that he
might initiate injection use of opiates if his cravings could not be controlled. The patient was placed
on methadone maintenance therapy.
Conclusion: While anecdotal reports indicate that initiation in prison of the use of addictive illicit
substances is frequent, documentation through clinical experience is rare, and the public health
implications of this behavior have not been given sufficient attention in the literature. Strategies of
incarcerating non-violent drug offenders and attempting to keep illicit drugs out of prisons have not
reduced the harms and costs of illicit drug use. Effective, practical alternatives are urgently needed;
expanded community diversion programs for non-violent drug offenders deserve particular
attention.
Background
In North America, policy-makers have primarily
responded to the public health emergency among injec-
tion drug users (IDU) by allocating resources to criminal
justice interventions. The reliance on law enforcement has
resulted in record incarceration rates in the United States
and Canada. [1] The incarceration of illicit drug users also
has major implications for public health because of the
potential for infectious disease transmission in prison. [2-
5] This may be of particular concern for human immuno-
deficiency virus (HIV) transmission, which has been pre-
viously documented among inmates in a Scottish prison
[4,6] and suspected in several other settings as a result of
syringe sharing between incarcerated injection drug users.
[7-9]
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The concentration of addicted individuals within prisons
is believed to result in elevated HIV risk behavior because
incarcerated IDU generally have high rates of HIV and
HCV, and the interventions that are available in the com-
munity, such as well managed agonist detoxification and
maintenance treatment and needle exchange, are often
not available in prison. [10] In addition to syringe shar-
ing, there are a number of other potential harms of mixing
addicted populations with other inmates. Here, we report
on a case of an opiate-addicted individual seeking metha-
done maintenance therapy (MMT) in the community
soon after his release from a Canadian prison.
Case presentation
A 20-year-old white male was seen as an outpatient at an
addiction medicine clinic in Calgary, Canada. The male
reported alcohol and cocaine use prior to being arrested,
and the patient acknowledged that chaotic behavior
related to the use of these substances had contributed to
his crimes and eventual incarceration. While incarcerated,
the individual reported initiating use of illicit (prescrip-
tion) opiates, and his preferred route of administration
was via nasal inhalation. Although the patient reported
that his fellow inmates had frequently injected (he even
reported assisting with injections), the patient denied
injection use of illicit drugs in prison. The patient reported
experiencing severe physical withdrawal symptoms dur-
ing periods of non-opiate use in prison and soon became
a regular user.
Upon release into the community, the patient reported
that he had continued his xuse of diverted pharmaceutical
opiates and that he had developed a pattern of use consist-
ent with severe physical addiction. At the time of presen-
tation at the clinic, the patient's urine tested positive for
opiates. At that time, the patient reported that his unstable
condition was such that he feared he might initiate intra-
venous opiate injection use if he did not do something to
control his opiate cravings. The patient did not say why he
had not injected opiates in prison but reported recogniz-
ing that injection opiate use would represent a further
negative progression of his opiate addiction. After some
discussion, the patient was started on methadone mainte-
nance therapy, 10 mg per day, increasing 10 mg per day
until desired therapeutic effect was reached.
Conclusion
We have described a case of an individual initiating opiate
addiction in a Canadian prison. With respect to this issue,
it is important to stress that initiation of the use of addic-
tive illicit substances while incarcerated has been previ-
ously reported. For instance, one study reported that 20%
of IDU surveyed initiated injection drug use in prison.
[11] However, while this is believed to occur frequently
(from anecdotal reports), it is rarely documented through
clinical experience. Accordingly, the public health and
social implications of initiation of illicit drug addiction in
prison have not received significant attention in the liter-
ature. This is of concern, since this issue has major impli-
cations for both prison and community health.
To date, the principal strategy to address initiation of
illicit drug use in prison has been to redouble efforts to
keep illicit drugs out of the prisons, though correction
officials concede that this is almost impossible. However,
over the last several decades, experience has proven that
more pragmatic solutions are available and can be effec-
tive. [10,12] One pragmatic strategy has been the provi-
sion of methadone maintenance therapy within the
prison system in an effort to reduce demand for illicit opi-
ates. Unfortunately, however, this strategy is likely to be
insufficient (e.g., for those who are primarily stimulants
users – a growing population), and it is noteworthy that
there was still illicit opiate use occurring in the prison
where the patient described in this report initiated his opi-
ate use, even though methadone was available there.
While the expansion and evaluation of addiction treat-
ment measures in prisons is an immediate priority, the
burgeoning levels of incarceration of drug users and the
rates of ongoing illicit drug use among incarcerated indi-
viduals indicate that additional strategies must be consid-
ered. [1-4,6-9] This implies that alternative programs to
incarceration, such as the treatment of addiction in the
community, may be more effective at reducing the health
and social harms and economic costs of illicit drug use.
[13,14] Expanded addiction services in prison should
therefore be coupled with expansion and evaluation of
community diversion programs for non-violent drug
offenders.
In this brief report, we have described a case of an individ-
ual initiating opiate use and developing dependency to
opiates within a Canadian prison. Unfortunately, this case
is not unique, [11] and the concerns it raises are relevant
to the many illicit drug users who do not use opiates in the
community but risk initiating opiate use (including intra-
venous use) when incarcerated. And although the risks of
HIV transmission in prison have been widely reported,
the implications of initiation of illicit drug addiction in
prison have not received adequate attention by public
health and correctional policy-makers. Effective practical
interventions are needed to address this concern, includ-
ing expansion of strategies involving expanded commu-
nity diversion programs for non-violent drug offenders.
These deserve particular attention, given their potential to
reduce HIV risk for current injectors who are incarcerated
and to reduce the prevalence of initiation of illicit drug
use (and, potentially, injecting) in the non-addicted
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